Daprodustat is a Small Molecule owned by GSK, and is involved in 37 clinical trials, of which 35 were completed, and 2 are ongoing.

Daprodustat acts by inhibiting hypoxia-inducible factor (HIF)-prolyl hydroxylases. Hypoxia-inducible factor (HIF), a heterodimeric nuclear factor, is a crucial intermediate in these defensive mechanisms. HIF is constitutively transcribed and translated. Its stability is drastically reduced by the oxygen dependent enzymatic hydroxylation of proline residues by prolyl hydroxylases (PHD). Hence these prolyl hydroxylase (PH) inhibitors selectively stimulate HIF-2 and HIF-1 mediated erythropoiesis for the treatment of anemia. The alpha subunit of HIF-1 is a target for prolyl hydroxylation by HIF prolyl-hydroxylase, which makes HIF-1 a target for degradation by an E3 ubiquitin ligase, leading to quick degradation by the proteasome.

The revenue for Daprodustat is expected to reach a total of $12bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Daprodustat NPV Report.

Daprodustat is originated and owned by GSK. Kyowa Kirin is the other company associated in development or marketing of Daprodustat.

Daprodustat Overview

Daprodusta (Duvroq) is an anti anemic agent. It is formulated as film coated tablets for oral route of administration. Duvroq indicated for the treatment of anaemia due to chronic kidney disease in adult patients not on dialysis and on dialysis.

The drug candidate can be applied topically as an ointment. It is a prolyl hydroxylase inhibitor.The drug candidate was also under development for the treatment of peripheral arterial disease (PAD)/peripheral vascular disease (PVD), ischemic events in patients undergoing thoracic aortic aneurysm repair, diabetic foot ulcer, wounds and tendon injuries.

GSK Overview

GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

The company reported revenues of (British Pounds) GBP34,114 million for the fiscal year ended December 2021 (FY2021), an increase of 0% over FY2020. In FY2021, the company’s operating margin was 18.1%, compared to an operating margin of 22.8% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 16.9% in FY2020. The company reported revenues of GBP7,829 million for the third quarter ended September 2022, an increase of 13% over the previous quarter.

Quick View – Daprodustat

Report Segments
  • Innovator (NME)
Drug Name
  • Daprodustat
Administration Pathway
  • Oral
  • Topical
Therapeutic Areas
  • Cardiovascular
  • Dermatology
  • Hematological Disorders
  • Metabolic Disorders
  • Musculoskeletal Disorders
Key Companies
  • Sponsor Company: GSK
  • Originator: GSK
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.